Enlivex Therapeutics Stock Today
| ENLV Stock | USD 1.09 0.03 2.68% |
PerformanceVery Weak
| Odds Of DistressLow
|
Enlivex Therapeutics is selling for under 1.09 as of the 21st of March 2025; that is 2.68 percent decrease since the beginning of the trading day. The stock's lowest day price was 1.09. Enlivex Therapeutics has less than a 11 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 21st of December 2024 and ending today, the 21st of March 2025. Click here to learn more.
Business Domain Software & Services | IPO Date 12th of December 1995 | Category Healthcare | Classification Information Technology |
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel. Enlivex Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 21.99 M outstanding shares of which 105.11 K shares are currently shorted by private and institutional investors with about 1.73 trading days to cover. More on Enlivex Therapeutics
Moving against Enlivex Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Enlivex Stock Highlights
| Executive Chairman | Shai MBA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Application Software, Software & Services, Information Technology, Information Technology, Software, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsEnlivex Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Enlivex Therapeutics' financial leverage. It provides some insight into what part of Enlivex Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Enlivex Therapeutics (ENLV) is traded on NASDAQ Exchange in USA. It is located in 14 Einstein Street, Ness Ziona, Israel, 7403618 and employs 6 people. Enlivex Therapeutics is listed under Application Software category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 24.63 M. Enlivex Therapeutics conducts business under Software sector and is part of Information Technology industry. The entity has 21.99 M outstanding shares of which 105.11 K shares are currently shorted by private and institutional investors with about 1.73 trading days to cover.
Enlivex Therapeutics currently holds about 62.48 M in cash with (23.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.4, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Enlivex Therapeutics Probability Of Bankruptcy
Ownership AllocationEnlivex Therapeutics holds a total of 21.99 Million outstanding shares. Enlivex Therapeutics shows 5.59 percent of its outstanding shares held by insiders and 22.15 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Enlivex Ownership Details
Enlivex Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Wells Fargo & Co | 2024-12-31 | 9.2 K | |
| Signaturefd, Llc | 2024-12-31 | 5 K | |
| Simplex Trading, Llc | 2024-12-31 | 3.4 K | |
| Jpmorgan Chase & Co | 2024-12-31 | 2.6 K | |
| Steward Partners Investment Advisory, Llc | 2024-12-31 | 2.5 K | |
| Bank Of America Corp | 2024-12-31 | 1.1 K | |
| Srs Capital Advisors Inc | 2024-12-31 | 1 K | |
| Bfsg, Llc | 2024-12-31 | 1000 | |
| Activest Wealth Management | 2024-12-31 | 1000 | |
| Armistice Capital, Llc | 2024-12-31 | 2.2 M | |
| Millennium Management Llc | 2024-12-31 | 633.8 K |
Enlivex Therapeutics Historical Income Statement
Enlivex Stock Against Markets
Enlivex Therapeutics Corporate Management
| Veronique AmorBaroukh | Senior Operations | Profile | |
| Shachar CPA | Chief Officer | Profile | |
| Oren Hershkovitz | Chief Officer | Profile | |
| Pr MD | Founder Officer | Profile |
Additional Tools for Enlivex Stock Analysis
When running Enlivex Therapeutics' price analysis, check to measure Enlivex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enlivex Therapeutics is operating at the current time. Most of Enlivex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Enlivex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enlivex Therapeutics' price. Additionally, you may evaluate how the addition of Enlivex Therapeutics to your portfolios can decrease your overall portfolio volatility.